ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / INSM / news
UTHR (83) ROIV (42) ALNY (53) VTRS (57) ⌘ Pro Terminal →

Why INSM Stock dropped -2.90% Today — RQD Quant Desk Flash

$109.31 -2.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $108.53

Insmed Incorporated (INSM) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $24.70B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on INSM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is INSM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Insmed Incorporated (NASDAQ: INSM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $109.31 (-2.90% 1D, market cap $24.70B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, INSM ranks #377 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does INSM compare to UTHR and ROIV in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INSM carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 79.7%, and ROIC of -35.0%. By comparison, UTHR (United Therapeutics Corporation) holds a A- grade (83/100 RQD, P/E 19.1x, ROIC 20.1%, cap $25.68B) and ROIV (Roivant Sciences Ltd.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -14.0%, cap $26.66B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for INSM?
▼

Per INSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001104506), Insmed Incorporated generated $606.4M in revenue (+66.7% YoY), -$1.28B in net income, and -$967.6M in free cash flow against $2.26B in total assets and $541.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $108.53 (-0.71%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (8)Whales (11)SEC (14)Macro (5)CEO (6)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$223 Bull$102 Base$80 Bear
📬 FREE INSM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for INSM)Realized 20D OHLCV Swing Band: ±9.8%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY INSM SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)

Altman Z-Score 5.25 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (25% of score)

20D Institutional Volume Accumulation (±9.8% realized swing band)

▼ #1 Drag / Risk Factor: Macro Regime Fit5/20 pts (-15 pt drag)

Macro rate sensitivity & RSI-14 (62.2) create a -15 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$97.79-3.8% Next Q
Q2 (-2Q)
39
Grade E$94.04+3.1% Next Q
Q3 (-1Q)
41
Grade D$96.98+12.7% Next Q
Current
44
Grade D$109.31-6.5% Hist 90D α
Trajectory: E (36) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a INSM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While INSM currently carries a cautious 44/100 (D) rating due to Macro Regime Fit (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($111.91) and Max Pain ($114.78) forces dealer call-delta covering toward $223.39.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $INSM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “INSM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why INSM Stock dropped -2.90% Today — RQD Quant Desk Flash

Insmed Incorporated (INSM) dropped -2.90% to $109.31, trading at 15% of its 52-week range ($90.39 – $212.75). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 15% of its 52-week range ($90.39 – $212.75) with RSI-14 at 62.2 (BULLISH MOMENTUM).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±9.8% around $109.31 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 79.7% gross margin and $0 annual free cash flow.
Live INSM Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring INSM)

  • ✓Walkthrough of INSM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
INSM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -21.93%📐 WEDGE COMPRESSION COIL
2026-11-03O $111.6H $112.6L $109.3C $109.3VOL 5.18M
RES: $115.3SUP: $92.82SMA50: $111.9SMA200: $124.7
$160.6$141.6$122.6$103.5$84.48RES $115.3SUP $92.82$109.32026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

INSM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 INSM Butterfly Map → + Track INSM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
14.6%/yr Implied 5Y Growth

vs. +66.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on INSM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for INSM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for INSM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (INSM)

Health Care Rank #377 of 1015 ⚔️ UTHR vs INSM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (INSM vs. UTHR, ROIV, ALNY, VTRS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Insmed Incorporated (INSM) ranks #377 by composite RQD confidence (44/100, grade D) and #63 by equity capitalization ($24.70B). Within this direct 5-issuer industry benchmark cohort, UTHR leads on earnings valuation at 19.1x trailing P/E, while ALNY leads on capital efficiency and profitability with 21.3% ROIC and 81.8% gross margin. UTHR currently holds the highest overall quantitative score in the immediate peer group at 83/100 (A-) compared with INSM at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
INSM ACTIVE
Insmed Incorporated
D 44/100 — 79.7% -35.0% -2.90% $24.70B Benchmark Subject
UTHR
United Therapeutics Corporation
A- 83/100 19.1x 87.9% 20.1% -0.43% $25.68B /uthr-vs-insm →
ROIV
Roivant Sciences Ltd.
D- 42/100 — — -14.0% -2.76% $26.66B /roiv-vs-insm →
ALNY
Alnylam Pharmaceuticals Inc.
D+ 53/100 74.2x 81.8% 21.3% -4.24% $22.10B /alny-vs-insm →
VTRS
Viatris Inc.
D+ 57/100 — 35.2% -8.1% -1.92% $21.86B /vtrs-vs-insm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001104506 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Insmed Incorporated (INSM) reported GAAP revenue of $606.4M (+66.7% vs. FY2024 revenue of $363.7M , and +98.7% cumulative change since FY2023) , GAAP net income of -$1.28B, operating cash flow of -$935.0M, and free cash flow of -$967.6M (-37.1% YoY). On the balance sheet, INSM closed FY2025 with $2.26B in total assets against $541.0M in total debt (Altman Z-Score: 5.25, Piotroski F-Score: 5/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $606.4M -$1.28B -$935.0M -$967.6M $2.26B $541.0M
FY2024 (FY) 2024-12-31 $363.7M -$913.8M -$683.9M -$705.8M $2.03B $1.10B
FY2023 (FY) 2023-12-31 $305.2M -$749.6M -$536.2M -$550.0M $13.40B $3.14B

3. INSM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is INSM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Insmed Incorporated (NASDAQ: INSM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $109.31 (-2.90% 1D, market cap $24.70B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, INSM ranks #377 in composite RQD confidence.

How does INSM compare to UTHR and ROIV in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), INSM carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 79.7%, and ROIC of -35.0%. By comparison, UTHR (United Therapeutics Corporation) holds a A- grade (83/100 RQD, P/E 19.1x, ROIC 20.1%, cap $25.68B) and ROIV (Roivant Sciences Ltd.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -14.0%, cap $26.66B). Among the 5-stock peer group, UTHR leads on earnings multiple (19.1x) while ALNY leads on capital efficiency (21.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for INSM?

Per INSM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001104506), Insmed Incorporated generated $606.4M in revenue (+66.7% YoY), -$1.28B in net income, and -$967.6M in free cash flow against $2.26B in total assets and $541.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is INSM trading relative to its 50-day, 200-day, and 52-week technical levels?

INSM last traded at $109.31 (-2.90% on volume of 4,241,739 shares), positioning the stock -2.32% below its 50-day simple moving average ($111.91) and -12.32% below its 200-day simple moving average ($124.67). Across its 52-week range of $90.39 to $212.75, INSM sits at the 15.5% percentile with a 14-day RSI of 62.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.8% ($98.60 to $120.02).

Direct Sub-Reports: INSM RQD Cockpit INSM 12M Forecast INSM Earnings & Move INSM Dividends & DRIP INSM Insiders & 13F INSM Whale Options INSM Profit Sankey INSM News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

INSM — Insmed Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Insmed Incorporated (INSM) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $109.31 (-2.90% 1D, market capitalization $24.70B).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 79.7%, operating margin of -60.0%, and free cash flow yield of -3.97%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (14/20): Incorporates a 1.03x equity beta, Altman Z-Score of 5.25, Piotroski F-Score of 5/9, and Debt/Equity of 0.73x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Insmed Incorporated (NASDAQ: INSM) is a Health Care issuer in the Biotechnology: Pharmaceutical Preparations industry. Per the market data, the company reports a gross margin of 79.7%. — for product lines, customer base, or revenue model detail.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Insmed Incorporated (INSM) reported $606.4M in annual revenue (up from $363.7M in FY2024, +66.7% YoY) and -$1.28B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($305.2M revenue, -$749.6M net income) through FY2025, INSM scaled operating cash flow to -$935.0M and free cash flow to -$967.6M, backed by $2.26B in total assets against $541.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -3.97% and institutional whale pillar of 11/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $90.39 – $212.75 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.03x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— no upstream or downstream links and no proprietary signals are recorded for INSM, so no supply-chain dependencies or sector correlations can be mapped from the provided sources.

  • Key Question #1: Can INSM sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $606.4M and free cash flow of -$967.6M, how will capital allocation balance growth reinvestment against $541.0M in total debt?
  • Key Question #3: How sensitive is INSM's 21.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.03x)?

INSM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Insmed Incorporated (INSM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to INSM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

INSM Bull vs. Bear Conversation Board — What's Your Call at $109.31?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON INSM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on INSM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $148.61 (+32.0%)
📌 Pinned Debate

Revenue grew from $305.2M in FY 2023 to $606.4M in FY 2025 while reported debt fell from $3.14B to $541.0M, and the Forensic Balance

Long INSM at $112.58 targeting $148.61. Revenue grew from $305.2M in FY 2023 to $606.4M in FY 2025 while reported debt fell from $3.14B to $541.0M, and the Forensic Balance Sheet pillar scored 14 / 20.. Institutional whale score is 11/20 and the risk/reward vs. the $90.39 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@RiskArb_Desk Fair point on 21.0x forward P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (79.7%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $91.19 (-19.0%)
Spot @ $112.58

Operating margin of -60% and FY 2025 FCF of -$967.6M, paired with ROIC of -35% and an RQD score of 44, leave cash economics unproven.

Here is the bear case nobody on the bull side wants to address on INSM: Operating margin of -60% and FY 2025 FCF of -$967.6M, paired with ROIC of -35% and an RQD score of 44, leave cash economics unproven.. At 21.0x forward P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%